" class="no-js "lang="en-US"> Moderna New Supply Agreement with Israel for 2022 - Medtech Alert
Saturday, June 10, 2023

Breaking News

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Sir Richard Roberts Elected to National Academy of Sciences Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Moderna New Supply Agreement with Israel for 2022 | Pharmtech Focus

April 21 2021

Moderna New Supply Agreement with Israel for 2022

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with Israel for 2022. Under the terms of this agreement, Israel also retains an option to purchase doses of one of Moderna’s variant-specific vaccine candidates subject to regulatory approval. Today’s announcement follows two earlier agreements between Israel and Moderna to supply a total of 10 million doses of the COVID-19 Vaccine Moderna. The Israeli Ministry of Health authorized COVID-19 Vaccine Moderna for use on January 4, 2021.

“We appreciate the continued confidence and collaboration with the Israel Ministry of Health with this new agreement,” said Stéphane Bancel, Chief Executive Officer of Moderna. “This is an important moment for our company as the first firm order for 2022 supply and for the supply of our variant-specific booster vaccine candidates against COVID-19, currently being studied in human clinical trials. Recent preclinical results have shown that our variant-specific booster candidates were effective against COVID-19 variants of concerns, and we hope to continue to see positive results from the clinical studies.”

People In This Post

Stephane Bancel

Stéphane Bancel

Companies In This Post

Moderna | Pharmtech Focus

Moderna
  1. Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration

    Gene Therapy

     Read more
  2. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

    Diseases

     Read more
  3. Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas

    Clinical Trials

     Read more
  4. Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

    News

     Read more
  5. Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

    Drug Development

     Read more
More On